Baxter International Inc.（BAX）財務資料BAXBaxter International Inc.

Baxter International Inc. (BAX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Infusion Therapies and Technologies, accounting for 59.0% of total sales, equivalent to $1.75B. Other significant revenue streams include Care and Connectivity Solutions and Advanced Surgery. Understanding this composition is critical for investors evaluating how BAX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Baxter International Inc. maintains a gross margin of 35.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.32%, while the net margin is 4.56%. These profitability ratios, combined with a Return on Equity (ROE) of -14.31%, provide a clear picture of how effectively BAX converts its operational activities into shareholder value.

In the context of the broader market, BAX competes directly with industry leaders such as COO and PEN. With a market capitalization of $13.29B, it holds a significant position in the sector. When comparing efficiency, BAX's gross margin of 35.41% stands against COO's 63.59% and PEN's 67.93%. Such benchmarking helps identify whether Baxter International Inc. is trading at a premium or discount relative to its financial performance.

Baxter reported a 5% increase in sales for Q2 2026, totaling $2.96 billion, and net income rose to $135 million, indicating some positive momentum despite prior losses.